Medication info
DIOPATH 80 mg Tablets (Valsartan)

DIOPATH 80 mg Tablets (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
Light red circular film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201104021 · Notified 2011.06.29 · Insurance code 642904250

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
* 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the drug be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this drug once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this drug once daily; do not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this drug orally twice daily, which may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this drug twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this drug to these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is used for the treatment of essential hypertension and helps reduce blood pressure. It is also suitable for heart failure patients who cannot use ACE inhibitors and is effective even in severe cases. It helps reduce the risk of mortality in patients with decreased left ventricular function after myocardial infarction. It is used for these three major diseases, contributing to the improvement of cardiovascular health in patients.

How to take

Adult dose

* 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the drug be taken at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this drug once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this drug once daily; do not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this drug orally twice daily, which may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this drug twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this drug to these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus, especially if taken during the second and third trimesters of pregnancy; therefore, it must be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or might become pregnant, nursing mothers, and patients with severe liver or kidney impairment, and certain hereditary angioedema patients should not take this medication. Elderly patients, patients with hyperkalemia, liver disease, and cardiovascular disease should take this medication with caution, as symptoms like hypotension may occur upon initial use, requiring close monitoring of their condition. Possible side effects during the use of this medication include headache, dizziness, cough, diarrhea, and fatigue, and serious side effects such as angioedema, renal dysfunction, and hepatitis may occur rarely, necessitating immediate consultation with healthcare personnel for any unusual symptoms. Particularly, patients with heart failure or post-myocardial infarction should monitor renal function closely, and simultaneous use with other antihypertensives or potassium-sparing diuretics may increase the risk of side effects due to interactions; consult a professional. Dizziness or drowsiness may occur while driving or operating machinery, so caution is needed. In case of overdose, severe hypotension or decreased consciousness may occur, requiring immediate emergency treatment, and should be stored out of reach of children.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Light red circular film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.